Skip to main content
. 2016 Dec 15;312(3):L309–L325. doi: 10.1152/ajplung.00357.2016

Fig. 10.

Fig. 10.

Capsazepine (CPZ) attenuates IPAH PASMC proliferation. A and B: representative images showing nuclear staining (top, Hoechst, blue), EdU staining (middle, AlexaFluor, red), and overlay images (bottom, overlay, purple) of normal and IPAH PASMCs incubated without (vehicle) or with 1, 10, and 40 μM CPZ for 48 h. C and D: summarized data (means ± SE) showing the percentage of cells with EdU incorporation (left) and the percentage of total cell number (right) in vehicle- and CPZ-treated normal and IPAH PASMCs (n = 3 separate experiments for normal and n = 9 separate experiments for IPAH). *P < 0.05 and ***P < 0.001 compared with control normal and IPAH PASMCs. E: summarized data (means ± SE) showing the percentage of total cell number in vehicle- and 10 μM CPZ-treated normal (left) and IPAH (right) PASMCs for 72 h (n = 3 separate experiments for normal and IPAH PASMCs, respectively). *P < 0.05 and ***P < 0.001 compared with control normal and IPAH PASMCs. F: representative Western blot images (left) showing the protein expression level of TRPV1 in normal PASMCs (top) and IPAH PASMCs (bottom) transfected with 80 pM scramble siRNA and 40 pM and 60 pM TRPV1 siRNA, respectively (n = 3). Summarized data (means ± SE) (right) showing the percentage of total cell number in 80 pM scramble siRNA- and 80 pM TRPV1 siRNA-treated normal and IPAH PASMCs for 48 h (n = 3 separate experiments for normal and IPAH PASMCs, respectively). *P < 0.05 and #P < 0.05 compared with scramble siRNA-treated normal and IPAH PASMCs.